ComplyRx
Built by ComplyRx

Compare clinical trial pipelines, export for presentations

dupilumab (16) vs upadacitinib (16)12 active2013–2030
dupilumabupadacitinib
Key
Actual date
Anticipated
Forecast to primary completion
RecruitingActive, not recruitingNot yet recruitingCompleted
'13
'15
'17
'19
'21
'23
'25
'27
'29
dupilumab
Open-label Study of Dupilumab in Patients With Atopic DermatitisP3
Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)P3
VENTUREP3
A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically AdvisableP3
VOYAGEP3
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)P3
Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)P2
IDEAP4
Level UpP3
TORNADOP4
AIM4:Next StepP4
WIDUSAP4
A Phase Ⅲ Comparative Study of QL2108 to Dupixent®P3
Tapering of Biologics in Chronic Rhinosinusitis With Nasal PolypsP4
HOTHOTP3
A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic DermatitisP2
upadacitinib
A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic TherapyP2
BALANCE-EXTENDP2
SELECT-NEXTP3
SELECT-EARLYP3
A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic DermatitisP2
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic TherapyP3
A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)P3
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)P3
Rising UpP3
SELECT-GCAP3
COVERP4
Level UpP3
Viti-UpP3
VICTRIVAP3
Ustekinumab and Upadacitinib for Induction and Maintenance Therapy in Patients With Refractory Crohn's Disease: A Multicenter, Randomized, Parallel-Controlled StudyP3
UP-FOR-UP4

Upcoming readouts

11 ahead · 2 drugs

Select a trial to load its full ClinicalTrials.gov record.

Trial Pipeline · How it works

Search, compare, export.

Three steps from drug name to a presentation-ready pipeline view, with live trial data, side by side.

  1. 01 · SEARCH

    Search drugs

    Type a drug name and see the phase 2-4 trials from ClinicalTrials.gov.

  2. 02 · COMPARE

    Compare timelines

    See start dates, primary completions, and status on one timeline, up to five drugs at once.

  3. 03 · EXPORT

    Export for your deck

    Download a branded PNG or PDF. Share the URL. Every comparison state is linkable.

FAQ

Where does the data come from?
All trial data is sourced from ClinicalTrials.gov (CTGov). Results are cached for up to 6 hours so repeat loads stay fast.
Is this free?
Yes. Compare up to five drugs and export PNG or PDF at no cost. Export requires a one-time email to join the ComplyRx waitlist.
What is ComplyRx?
ComplyRx is an all-in-one marketing/competitive intelligence platform for organisations and individuals that work in healthcare, life sciences, and the pharmaceutical industry.
Join the waitlist

Be the first to access ComplyRx

We'll let you know as soon as your spot opens to use ComplyRx.

By joining, you agree to our Privacy Policy.